English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  Molecular characterization of Noonan Syndrome

Musante, L. (2003). Molecular characterization of Noonan Syndrome. PhD Thesis, Università degli Studi di Torino, Torino, Italy.

Item is

Files

show Files
hide Files
:
PhD-Musante.pdf (Any fulltext), 4MB
 
File Permalink:
-
Name:
PhD-Musante.pdf
Description:
-
OA-Status:
Visibility:
Restricted (Max Planck Institute for Molecular Genetics, MBMG; )
MIME-Type / Checksum:
application/pdf
Technical Metadata:
Copyright Date:
-
Copyright Info:
eDoc_access: MPG
License:
-

Locators

show

Creators

show
hide
 Creators:
Musante, Luciana1, Author           
Affiliations:
1Familial Cognitive Disorders (Luciana Musante), Dept. of Human Molecular Genetics (Head: Hans-Hilger Ropers), Max Planck Institute for Molecular Genetics, Max Planck Society, ou_1479644              

Content

show

Details

show
hide
Language(s): eng - English
 Dates: 2003
 Publication Status: Accepted / In Press
 Pages: 126 pp
 Publishing info: Torino, Italy : Università degli Studi di Torino
 Table of Contents: 1. INTRODUCTION..............................................................................................................5
1.1 HISTORY...........................................................................................................................5
1.2 CLINICAL FEATURES...........................................................................................................6
1.2.1 Craniofacial features..............................................................................................6
1.2.2 Cardiovascular anomalies......................................................................................7
1.2.3 Growth....................................................................................................................8
1.2.4 Skeletal findings......................................................................................................8
1.2.5 Genitourinary system..............................................................................................9
1.2.6 Haematology............................................................................................................9
1.2.7 Lymphatics...............................................................................................................9
1.2.8 Development and behaviour..................................................................................10
1.2.9 Hearing anomalies.................................................................................................10
1.2.10 Ocular anomalies...................................................................................................10
1.2.11 Ectoderm................................................................................................................10
1.3 GENETIC STUDIES............................................................................................................12
1.4 GENETIC HETEROGENEITY................................................................................................15
1.4.1 Noonan syndrome 2 (MIM 605275)......................................................................15
1.4.2 Neurofibromatosis-Noonan syndrome (NF-NS) (MIM 601321)...........................16
1.4.3 LEOPARD syndrome (MIM #151100)..................................................................18
1.4.4 Cardio-facio-cutaneous syndrome (CFC)(MIM 115150).....................................18
1.5 CHROMOSOMAL REARRANGEMENTS IN HUMANS.................................................................20
1.5.1 Numerical chromosomal abnormalities................................................................22
1.5.2 Structural chromosomal rearrangements.............................................................21
1.5.3 Disease-associated balanced chromosome rearrangements: a genetic tool for gene identification and cloning..........................................................................................22
1.6 AIMS AND OBJECTIVE.......................................................................................................24
2. MATERIALS AND METHODS....................................................................................25
2.1 MATERIALS......................................................................................................................25
2.1.1 Chemicals and equipment.....................................................................................25
2.1.2 Solutions and media..............................................................................................26
2.1.3 Buffer solutions.....................................................................................................27
2.1.4 Enzymes.................................................................................................................28
2.1.5 Kits........................................................................................................................29
2.1.6 Vectors..................................................................................................................29
2.1.7 Primers..................................................................................................................29
2.1.8 Genomic material..................................................................................................34
2.1.9 Bacterial material.................................................................................................34
2.2 METHODS........................................................................................................................35
2.2.1 Patients' sample collection...................................................................................35
2.2.2 Bioinformatic analysis..........................................................................................35
2.2.3 DNA isolation........................................................................................................36
2.2.4 RNA isolation........................................................................................................36
2.2.5 Fluorescence in Situ Hybridisation (FISH)..........................................................36
2.2.6 Polymerase Chain Reaction (PCR)......................................................................37
2.2.7 Allele-Specific PCR amplification (ASO).............................................................38
2.2.8 RT-PCR.................................................................................................................38
2.2.9 Semiquantitative RT-PCR.....................................................................................38
2.2.10 Purification of PCR products................................................................................39
2.2.11 Recombinant DNA techniques..............................................................................39
2.2.12 Sequencing............................................................................................................39
2.2.13 5'-RACE (Rapid Amplification of cDNA Ends)....................................................39
2.2.14 Labelling of DNA probes for hybridisations.........................................................40
2.2.15 Library screening..................................................................................................41
2.2.16 Southern blot hybridisations.................................................................................42
2.2.17 Northern blot hybridisations.................................................................................42
2.2.18 Mutation screening by Denaturing High Performance Liquid Chromatography (DHPLC)...........................................................................................................................43
3. RESULTS........................................................................................................................44
3.1 MOLECULAR CHARACTERIZATION OF THE BREAKPOINT REGIONS ASSOCIATED
WITH A CONSTITUTIONAL T(2;12)(Q37;Q24)PAT IN A PATIENT WITH NOONAN SYNDROME ..............44
3.1.1 Case report............................................................................................................44
3.1.2 Identification of chromosome-specific BAC clones that spanned the translocation breakpoints........................................................................................................................45
3.1.3 Chromosome 12: cosmid library screening and Southern blot experiments........48
3.1.4 Chromosome 2: cosmid library screening and Southern blot experiments..........49
3.1.5 In silico analysis of the breakpoint-spanning BAC clone on chromosome 12.....51
3.1.6 Molecular analysis of the breakpoint region on chromosome 12.........................52
3.1.7 Identification and characterization of the TRAP240-like gene............................54
3.1.8 Expression analysis of the TRAP240-like gene....................................................58
3.1.9 Expression analysis of the TRAP240-like gene in the patient with t(2;12)(q37;q24)pat...........................................................................................................59
3.1.10 Mutation analysis of the candidate gene TRAP240-like.......................................60
3.1.11 Analysis of the breakpoint region on chromosome 2............................................65
3.2 PTPN11 GENE ANALYSIS....................................................................................................67
3.2.1 Mutation analysis of the PTPN11 gene in 96 NS and 5 CFC patients.................67
3.2.2 Mutation analysis of the PTPN11 gene in patients with LEOPARD syndrome...71
4. DISCUSSION...................................................................................................................74
4.1 ROLE OF PTPN11 GENE IN THE AETIOLOGY OF NOONAN SYNDROME, CARDIO-FACIO-CUTANEOUS SYNDROME, AND LEOPARD SYNDROME..........................................................................................74
4.1.1 Spectrum of PTPN11 mutation in NS patients......................................................77
4.1.2 Genotype-phenotype correlation..........................................................................82
4.1.3 Cosegregation.......................................................................................................86
4.1.4 Cardio-facio-cutaneous syndrome........................................................................86
4.1.5 LEOPARD syndrome............................................................................................87
4.2 ROLE OF TRAP240-LIKE GENE IN THE AETIOLOGY OF NOONAN SYNDROME.............................89
4.3 SELENOCYSTEINE LYASE GENE................................................................................................94
4.4 CONCLUSION........................................................................................................................98
5. REFERENCES...............................................................................................................100
6. SUMMARY....................................................................................................................116
6.1 RIASSUNTO....................................................................................................................116
6.2 SUMMARY......................................................................................................................119
7. APPENDIX.....................................................................................................................124
7.1 PUBLICATIONS...............................................................................................................124
7.2 ACKNOWLEDGMENTS.....................................................................................................126
 Rev. Type: -
 Identifiers: eDoc: 194830
 Degree: PhD

Event

show

Legal Case

show

Project information

show

Source

show